Picture EBD Group World of Partnering Opportunities 650x100px

Document › Details

Autolus Therapeutics Ltd.. (5/8/18). "Press Release: Autolus Files for Proposed Initial Public Offering in the United States". London.

	Region	United States (USA)
	Organisation	Autolus Therapeutics Ltd.
	Today	Autolus Therapeutics plc (Nasdaq: AUTL)
	Group	Autolus Therapeutics plc (Nasdaq: AUTL)
	Organisation 2	Nasdaq Global Market
	Group	Nasdaq OMX (Group)
	Product	T cell therapy
	Product 2	investment banking
	Person	Noonan, Susan A. (S.A. Noonan Communications before Noonan/Russo Communications)
	Person 2	Wilson, Julia (Achilles Therapeutics 202011 Head of Communications + JW Communications 201209– before Vectura Group)

Autolus Limited (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it has filed a registration statement on Form F-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share. All ADSs to be sold in the proposed IPO will be offered by Autolus. Autolus intends to apply to list its ADSs on the Nasdaq Global Market under the ticker symbol “AUTL.” The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.

The Registration Statement relating to the ADSs has been filed with the SEC but has not yet become effective. The ADSs may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.

The Registration Statement can be accessed through the SEC’s EDGAR database and contains further information relating to Autolus.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

The securities referred to in this announcement are to be offered only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from either of the joint book-running managers for the offering, Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at +1 866 471 2526 or by email at prospectusgroup-ny@ny.email.gs.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at + 1 877 547 6340, or by email at Prospectus_Department@Jefferies.com.

Investor Contact:

S.A. Noonan Communications, LLC
Susan A Noonan
212 966 3650
susan@sanoonan.com

Media Contact:

JW Communications
Julia Wilson
+44 (0)7818 430877
juliawilsonuk@gmail.com

About Autolus

Autolus is a clinical-stage, biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumours.

Record changed: 2023-06-05